Encompass Health Corporation EHC Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | 10%+1.1pp | 9.5%+1.1pp | 9.3%+1.2pp | 9.2%+1.3pp | 9%+1.4pp | |
| Returns | ||||||
| Return on equity | 26%+0.7pp | 25.1%+0.6pp | 25%+1.0pp | 25.4%+1.3pp | 25.4%+1.3pp | |
| Return on invested capital | 16.7%+1.5pp | 16.3%+2.1pp | 15.8%+2.1pp | 15.6%+2.3pp | 15.2%+2.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | |
| Liquidity | ||||||
| Current ratio | 1.2×+0.1× | 1.1×0.0× | 1.1×+0.1× | 1.1×-0.3× | 1.1×-0.3× | |
| Leverage | ||||||
| Debt-to-equity | 1.2×-0.2× | 1.3×-0.3× | 1.3×-0.4× | 1.4×-0.4× | 1.5×-0.4× | |
| Net debt / EBITDA | 2×-0.4× | 2.1×-0.5× | 2.2×-0.6× | 2.3×-0.6× | 2.4×-0.5× | |
| Per Share | ||||||
| Book value per share | $25.07+18.5% | $23.86+18.0% | $23.20+20.9% | $22.29+23.6% | $21.15+24.1% | |
| Valuation | ||||||
| Market capitalization | $9.62B-5.7% | $10.68B+14.8% | $12.79B+32.5% | $12.19B+42.4% | $10.2B+23.8% | |
| Price / earnings | 15.8×-4.8× | 18.9×-1.6× | 23.6×+0.8× | 23.3×+1.9× | 20.6×-1.3× | |
| Price / sales | 1.6×-0.3× | 1.8×+0.1× | 2.2×+0.4× | 2.2×+0.5× | 1.9×+0.2× | |
| Price / book | 3.8×-0.9× | 4.4×-0.1× | 5.4×+0.5× | 5.3×+0.7× | 4.7×0.0× | |
| EV / EBITDA | 8.6×-2.0× | 9.7×-0.7× | 11.7×+0.5× | 11.6×+1.0× | 10.6×-0.1× | |
| Dividend yield | 0.8%+0.1pp | 0.7%0.0pp | 0.5%-0.1pp | 0.6%-0.2pp | 0.6%-0.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Encompass Health Corporation's ratios come from?
- Every ratio is computed from Encompass Health Corporation's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
